Can rosuvastatin cause nocturia (frequent nighttime urination)?

Rosuvastatin Does Not Directly Cause Nocturia, But May Contribute Through Proteinuria and Hematuria

Rosuvastatin is not a recognized direct cause of frequent nighttime urination (nocturia), though FDA labeling documents proteinuria and hematuria as known adverse effects that could theoretically contribute to urinary symptoms. 1

Evidence from FDA Drug Labeling

The official FDA labeling for rosuvastatin explicitly warns about proteinuria and hematuria, particularly at the 40 mg dose 1. These findings were:

• More frequent with rosuvastatin 40 mg compared to lower doses
• Generally transient
• Not associated with worsening renal function in clinical trials
• The FDA recommends dose reduction for unexplained persistent proteinuria and/or hematuria

However, nocturia is not listed among the adverse reactions in the FDA labeling. The most common side effects (≥2%) were headache, nausea, myalgia, asthenia, and constipation 1.

Real-World Evidence Shows Small But Measurable Signal

A 2014 FDA Adverse Event Reporting System (FAERS) analysis found a small but statistically significant signal for lower urinary tract symptoms with statins 2:

• Rosuvastatin showed significant disproportionality for both voiding symptoms (ROR 1.16) and storage symptoms (ROR 1.25)
• For nocturia specifically, a significant signal was detected
• The reporting odds ratios were modest, suggesting this is an uncommon effect

More concerning, a 2022 real-world study of 152,101 rosuvastatin users found 3:

• 2.9% developed hematuria and 1.0% developed proteinuria over median 3.1 years follow-up
• Rosuvastatin carried 8% higher risk of hematuria and 17% higher risk of proteinuria compared to atorvastatin
• 44% of patients with eGFR <30 ml/min/1.73m² were prescribed doses exceeding the FDA-recommended 10 mg maximum
• Risk increased with higher doses

Clinical Context: Nocturia Has Multiple Causes

The comprehensive 2022 European Urology guidelines on nocturia emphasize that medical conditions and medications must be systematically evaluated 4. The guidelines recommend:

1. Complete a bladder diary to distinguish between nocturnal polyuria (>33% of 24-hour output at night) versus reduced bladder capacity
2. Review all medications that could contribute, particularly diuretics, but also medications affecting fluid balance
3. Assess for underlying conditions: diabetes, heart failure, chronic kidney disease, sleep disorders, hypertension

The guidelines specifically note that medication adjustment is important, but must consider the condition for which the medication was prescribed 4. Since rosuvastatin provides cardiovascular mortality benefit, the medical condition generally takes priority over nocturia symptoms.

Practical Recommendations

If a patient on rosuvastatin develops nocturia:

1. Do not automatically attribute it to rosuvastatin - nocturia is multifactorial and common (especially in older adults)

2. Check urinalysis for proteinuria and hematuria 1:

   • If present and persistent, consider dose reduction per FDA guidance
   • If patient is on 40 mg and has eGFR <30, dose should not exceed 10 mg 3

3. Complete proper nocturia evaluation 4, 5:

   • 3-day bladder diary to quantify nocturnal polyuria
   • Blood pressure measurement
   • Review for diabetes, heart failure, chronic kidney disease
   • Assess sleep quality and sleep disorders
   • Review ALL medications, especially diuretics timing

4. Consider switching to atorvastatin if rosuvastatin-related renal effects are suspected, as atorvastatin showed lower rates of hematuria and proteinuria 3

5. Do not discontinue statin therapy without cardiology consultation, as cardiovascular benefits typically outweigh urinary symptoms 4

Key Caveat

The association between rosuvastatin and nocturia appears weak and indirect, likely mediated through renal effects (proteinuria/hematuria) rather than direct bladder or urinary tract effects. Most patients with nocturia on rosuvastatin have other more likely causes that should be systematically evaluated per the nocturia guidelines 4.